GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ACADIA Pharmaceuticals Inc (NAS:ACAD) » Definitions » Cyclically Adjusted FCF per Share

ACADIA Pharmaceuticals (ACADIA Pharmaceuticals) Cyclically Adjusted FCF per Share : $-1.25 (As of Mar. 2024)


View and export this data going back to 2004. Start your Free Trial

What is ACADIA Pharmaceuticals Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

ACADIA Pharmaceuticals's adjusted free cash flow per share for the three months ended in Mar. 2024 was $0.175. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-1.25 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -5.60% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -7.10% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was -1.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of ACADIA Pharmaceuticals was 13.60% per year. The lowest was -8.70% per year. And the median was -2.20% per year.

As of today (2024-06-10), ACADIA Pharmaceuticals's current stock price is $14.89. ACADIA Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was $-1.25. ACADIA Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is .


ACADIA Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

The historical data trend for ACADIA Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ACADIA Pharmaceuticals Cyclically Adjusted FCF per Share Chart

ACADIA Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.00 -1.07 -1.18 -1.28 -1.26

ACADIA Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.30 -1.30 -1.33 -1.26 -1.25

Competitive Comparison of ACADIA Pharmaceuticals's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, ACADIA Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ACADIA Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where ACADIA Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



ACADIA Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ACADIA Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.175/131.7762*131.7762
=0.175

Current CPI (Mar. 2024) = 131.7762.

ACADIA Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.171 100.560 -0.224
201409 -0.177 100.428 -0.232
201412 -0.184 99.070 -0.245
201503 -0.263 99.621 -0.348
201506 -0.304 100.684 -0.398
201509 -0.318 100.392 -0.417
201512 -0.346 99.792 -0.457
201603 -0.372 100.470 -0.488
201606 -0.577 101.688 -0.748
201609 -0.423 101.861 -0.547
201612 -0.507 101.863 -0.656
201703 -0.584 102.862 -0.748
201706 -0.484 103.349 -0.617
201709 -0.477 104.136 -0.604
201712 -0.241 104.011 -0.305
201803 -0.366 105.290 -0.458
201806 -0.328 106.317 -0.407
201809 -0.346 106.507 -0.428
201812 -0.301 105.998 -0.374
201903 -0.451 107.251 -0.554
201906 -0.266 108.070 -0.324
201909 -0.130 108.329 -0.158
201912 -0.194 108.420 -0.236
202003 -0.321 108.902 -0.388
202006 -0.254 108.767 -0.308
202009 -0.155 109.815 -0.186
202012 -0.185 109.897 -0.222
202103 -0.383 111.754 -0.452
202106 -0.158 114.631 -0.182
202109 -0.106 115.734 -0.121
202112 -0.142 117.630 -0.159
202203 -0.473 121.301 -0.514
202206 -0.081 125.017 -0.085
202209 -0.004 125.227 -0.004
202212 -0.147 125.222 -0.155
202303 -0.111 127.348 -0.115
202306 0.050 128.729 0.051
202309 -0.359 129.860 -0.364
202312 0.518 129.419 0.527
202403 0.175 131.776 0.175

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


ACADIA Pharmaceuticals  (NAS:ACAD) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


ACADIA Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of ACADIA Pharmaceuticals's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


ACADIA Pharmaceuticals (ACADIA Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Executives
Austin D. Kim officer: EVP & General Counsel C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Brendan Teehan officer: EVP, COO, Head of Commercial C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Stephen Davis director, officer: PRESIDENT AND CEO ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
James Kihara officer: Principal Accounting Officer C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Mark C. Schneyer officer: Chief Financial Officer C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Laura Brege director C/O ONYX PHARMACEUTICALS, INC., 2100 POWELL STREET, EMERYVILLE CA 94608
Baker Bros. Advisors Lp 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Douglas J Williamson officer: Executive VP, Research & Dev AVADEL PHARMACEUTICALS PLC, 10 EARLSFORT TERRACE, DUBLIN L2 D02 T390
Srdjan R. Stankovic officer: EVP C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Adora Ndu director C/O DBV TECHNOLOGIES S.A., 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0 92120
Elena Ridloff officer: EVP and CFO C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Michael J. Yang officer: EVP AND CCO C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Elizabeth A. Garofalo director C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
James M Daly director INCYTE CORPORATION EXPERIMENTAL STATION, RTE 141 & HENRY CLAY RD. BLDG E336, WILMINGTON DE 19880
Eric Alejandro Miller officer: Controller & PAO C/O ACADIA PHARMACEUTICALS INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130